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Mycobacterium tuberculosis and human immunodeﬁciency virus (HIV) co-infections
have remained a major public health concern worldwide, particularly in Southern Af-
rica. Yet our understanding of the molecular interactions between the pathogens has
remained poor due to lack of suitable preclinical models for such studies. We reviewed
the use, this far, of mammalian cell culture models in HIV–MTB interaction studies.
Studies have described the use of primary human cell cultures, including (1) monocyte-
derived macrophage (MDM) fractions of peripheral blood mononuclear cell (PBMC),
alveolar macrophages (AM), (2) cell lines such as the monocyte-derived macrophage cell
line (U937), T lymphocyte cell lines (CEMx174, ESAT-6-speciﬁc CD4+ T-cells) and an
alveolar epithelial cell line (A549) and (3) special models such as stem cells, three
dimensional (3D) or organoid cell models (including a blood–brain barrier cell model) in
HIV–MTB interaction studies. The use of cell cultures from other mammals, including:
mouse cell lines [macrophage cell lines RAW 264.7 and J774.2, ﬁbroblast cell lines (NIH
3T3, C3H clones), embryonic ﬁbroblast cell lines and T-lymphoma cell lines (S1A.TB,
TIMI.4 and R1.1)]; rat (T cells: Rat2, RGE, XC and HH16, and alveolar cells: NR8383)
and primary guinea pigs derived AMs, in HIV–MTB studies is also described. Given the
spectrum of the models available, cell cultures offer great potential for host-HIV–MTB
interactions studies.1. Introduction
Tuberculosis (TB) and HIV/AIDS remain the two most
important human communicable diseases globally, especially in
Southern Africa. In 2012 alone, an estimated 12 million people
worldwide reportedly suffered from active TB and 36.9 million
people were living with HIV [1]. At least 30% of the people livingwith HIV worldwide are reportedly infected withMycobacterium
tuberculosis (M. tuberculosis, MTB) [2]. An estimated 9.6 million
new cases of TB were recorded worldwide in 2014 alone, of
which 1.5 million died and 0.4 million were co-infected with
HIV [1]. Co-infection with HIV and MTB reportedly contributes
to the transition of the latter from latency into active TB disease
[3]. Active MTB infections reportedly contribute to HIV
pathogenesis by promoting increased immune activation and an
associated immune exhaustion, which ultimately leads to
immune collapse [4]. Furthermore, co-infection of an individual
with MTB and HIV is known to complicate the diagnosis and
treatment of the two diseases [5].
Co-infection studies are complex as they superimpose multi-
factorial pathogenic pathways associated with each disease.ess article under the CC BY-NC-ND license (http://
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contributions of each co-infecting pathogen and to assess the
summative and synergistic effect of their interactions. In co-
infection studies, three major levels of investigation can be
used. Level one involves examining responses of cells from
mono-infected patients in comparison with those infected with
the other pathogen [6]. The second level involves the
examination of infected cells from patients (or animal hosts)
infected with one disease against the effects of the other
causative agent. Level three involves the infection of cell
culture model systems with one or both pathogens. The third
approach, which is the focus of this review, is the one that
provides information on the mechanisms that are involved in
mono- and co-infections.
The use of cell culture models has, this far, furthered our
understanding of interactions between the human host and the
two pathogens (HIV and/or MTB) at the level of the cell, and
contributed immensely to drug discovery. However, crucial gaps
remain in our understanding of the host-HIV–MTB interactions
at the molecular level. This may be attributed, in part, to the lack
of robust in vitro cell models for such studies, since model
systems that allow entry and propagation of the pathogens
remain largely unappraised. The lack of a robust cell culture
system for the two pathogens is a result of the fact that the
pathogens are frequently studied separately in cell and animal
models. This article therefore assesses, based on studies this far,
the potential of cell cultures as models to study HIV–MTB co-
infections.
Use or failure to use one cell culture model or another for co-
infection studies is dependent on the ability of the two pathogens
to infect and replicate in the cells that make up the supposed
model. M. tuberculosis has a tropism for phagocytic cells,
particularly alveolar macrophages (AMs) and lung dendritic
cells (DC). These cell types constitute the majority of lung an-
tigen presenting cells (APC) and defence against pulmonary
infection by phagocytosing foreign particles and presenting
these antigens to immune cells [7]. While the macrophage is
generally considered a primary target cell for MTB, AMs are
most important in the case of pulmonary TB. In fact,
attachment of MTB cells to AMs represents the earliest phase
of primary infection in pulmonary TB [7].
In HIV-1 infection, the CD4+ T lymphocyte is the primary
target cell [8]. However, the virus is also able to infect
macrophages, monocytes, DC, epithelial cells (especially the
anogenital mucosa) and microglial cells [8]. While loss of
CD4+ T cells and systemic immune hyperactivation are the
hallmarks of primary HIV infection, the end of the acute
infection is associated with the emergence of speciﬁc CD4+
and CD8+ T cell responses and the establishment of a chronic
phase infection [9]. While other cells may harbour HIV
infectious agents, especially DCs, such cells may not generate
productive infections [10]. Macrophages, which are located at
various systemic sites, especially the gastrointestinal mucosa,
constitute a major cellular reservoir for the virus [11].
During the early years of the epidemic, HIV strains were
characterized as macrophage tropic (M-tropic), CD4+ T cell
tropic (T-tropic) or both (dual tropic) [12]. The tropism for HIV is
determined by the expression of both CD4 receptors and CeC
chemokine receptor type 5 (CCR5)/alpha-chemokine (CXCR4)
co-receptors (R5 and X4 viruses, respectively) [13]. Notably,
the HIV particles that are transmitted between individuals,
referred to as transmitted or founder viruses are R5 strains [14]that are minimally tropic for macrophages and DCs –
implying that the infection of macrophages occurs at a later
stage after viral transmission [15]. Vaginal and urethral
macrophages, but not intestinal macrophages, have indeed
been shown to be the initial cell targets for R5 HIV-1 after the
translocation of the virus across the epithelium [15]. It has been
shown that HIV-1-speciﬁc antibodies and CD8+ cytotoxic T
cells are detected in most HIV-1-infected people, yet HIV-1
infection is not eradicated. This is a result of the failure of
DCs to sense HIV-1 during acute infection and hence, failure to
effectively activate naive HIV-1-speciﬁc T cells [16]. DCs play
an important role in transporting virus from initial infection
sites (usually the genital mucosa) to the draining lymph nodes.
Furthermore, the progression of HIV or MTB within a host is
controlled by an interplay between the interacting pathogens and
a number of host-speciﬁc factors, especially those that are
associated with cellular immunity [17]. Both HIV and MTB are
known to modulate the function of many immune cells,
including macrophages, DCs and CD4+ and CD8+ T cells in
humans [17]. While alveolar macrophages are the initial target
for MTB [18], they can also be infected with HIV [17]. The
pathways by which MTB enhances HIV replication in co-
infected macrophages, as shown so far, include the modulation
of an enhancer binding protein beta transcription factor
(CCAAT) [19], interleukins 1b(IL-1b), IL-6 and IL-8, and
granulocyte-macrophage colony-stimulating factor (GM-CSF)
production [20] and the activation of the NF-kB pathway [21].
In short, both HIV and MTB show variable tropisms for
speciﬁc cells, particularly alveolar macrophages [22], depending
on the receptors that are expressed on the surfaces of recipient
cells. While the mechanisms that underlie the interactions
between HIV or MTB and the host cell are starting to emerge,
there remains a need to identify the full complement of
receptors and cell-based immune factors that inﬂuence HIV-1/
MTB co-infections. Cell culture models, especially those of
human origin, can offer a tractable system to understand host–
pathogen interactions without the need to use animal or human
subjects.
2. Immortalised and primary cell culture models in
host–pathogen interaction studies
Immortalised cell lines and primary cell cultures, both of
which are often used in host–pathogen interaction studies, offer
several advantages over patient-based studies. These include the
fact that they are cost effective, easy to use and are often ethically
acceptable alternative models of human disease [23].
Immortalisation makes these cells less physiologically relevant
than primary cells as models for host–pathogen interaction
studies. However, a few immortalised cell cultures including a
mouse AM cell line (MH-S) and a human ovarian surface
epithelium cell line (HOSE1 line) are known to behave like
primary cells [24]. The immortalised cells offer exclusive
advantages over other cell cultures in that they are readily
infected with both pathogens, have high proliferation rates and
long lifespans, maintain their phenotype in culture, provide
enough experimental source materials for extensive study and
produce homogenous cell populations which ensure consistency
and reproducibility of ﬁndings [23]. For these reasons,
immortalised cell cultures have become a standard in vitro tool
for host–pathogen interaction studies despite the inherent failure
of these models to fully simulate human diseases.
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HIV or MTB studies has been demonstrated [25]. Primary cell
cultures offer an added advantage over immortalised cells in
that they closely mimic the environment of pathogens in vivo
[26]. However, the use of primary or immortalised cultured
cells is limited by a number of inherent weaknesses, including
the fact that (i) most immortalised cell lines cannot fully
mimic the in vivo cell conditions, [27] (ii) structures on the
surface of cultured cells, including receptors, are increasingly
modiﬁed with increase in the passage number, [28] (iii)
cultured cells lack access to the native environment that
typically modulates their phenotype in vivo [28] and (iv) the
cells do not retain in vivo functionality and morphology [29].
Primary cell culture models present an additional limitation in
that they are practically difﬁcult to propagate to sufﬁcient
numbers for host–pathogen interaction experiments [30].
Hence, primary cells and immortalised lines are not optimal
models for highly specialized cell types that characterise
diseased tissue in vivo. To circumvent challenges posed by
immortalised and primary cell cultures in host–pathogen
interactions, stem cell culture models have emerged, which
include pluripotent cells.
3. Cell culture models for HIV–MTB co-infection
studies
3.1. The potential of human-derived primary cell
cultures as models for HIV–MTB co-infection studies
3.1.1. Human peripheral blood mononuclear cells
(PBMCs)
The use of PBMCs, including lymphocytes and monocytes in
HIV–MTB co-infection studies has also been described. The
successful use of PBMCs in host–pathogen interaction studies
has permitted the elucidation of basic pathogenic mechanisms,
including the demonstration of the enhancement effect of MTB
on HIV replication, relying on the modulating function of
monocytes, tumour necrosis factor alpha (TNF-a) and monocyte
chemo-attractant protein-1 (MCP-1) cytokine pathways [31]. A
recent study by Wilkinson et al. [32] demonstrated the
occurrence of tuberculosis-associated immune reconstitution in-
ﬂammatory syndrome among HIV–TB-co-infected patients
commencing antiretroviral therapy (ART) using an ex vivo cul-
ture of PBMCs. In the same study, Wilkinson et al. [31]
demonstrated that infection with MTB and ART inﬂuences
gene expression in freshly isolated and cultured PBMCs from
HIV-infected individuals. Vijayakumar et al. [25] described the
use of an in vitro cell model comprising PBMCs and
monocyte-derived macrophages (MDM) in a study on in-
teractions between Mycobacterium bovis (M. bovis) BCG and
HIV-1, as well as in drug toxicity and activity studies in a co-
infection. Subsets of the PBMCs, especially monocytes and T
cells, have provided important information on the attachment,
entry and replication ofMTB and HIV, making such cells a useful
platform for complex host-HIV–MTB interaction studies [25].
3.1.2. Human ex vivo monocyte derived macrophages
(MDM)
The use of ex vivoMDM cultures, a fraction of the PBMC, in
TB and HIV research has also been described [33]. Campbell
et al. [34] showed a link between autophagy in human MDMand vitamin D3-induced innate immunity, and consequently
demonstrated the potential of vitamin D3 as therapy for HIV–
MTB infections. Furthermore, MDM have been used as a model
for transcriptomic and proteomic proﬁling of HIV or MTB in
host macrophages [35,36]. Chertova et al. [35] detected at least
250 host proteins and at least 29 viral proteins in HIV infected
human MDM. Ragno et al. [36] demonstrated the modulation
of a number of TB related factors in MDM. The fact that
macrophages constitute a reservoir for both HIV and MTB
[11,37] and that these cells specialise in internalising
intracellular pathogens, makes these cells a convenient tool to
study HIV–MTB co-infections.
3.1.3. Human ex vivo alveolar macrophages (AM)
In addition to the human MDM, the use of AM, which are
differentiated from monocytes and obtained by bronchiolar
lavage, in studies that seek to understand interactions between
the host and HIV-1/MTB has also been described [38]. Through
the use of human AM, Spira et al. [39] demonstrated the
importance of the modulation of TNF-a expression in
defending the host against tuberculosis. Furthermore, Silver
et al. [40] showed that infection of an individual with the
H37Rv strain of MTB upregulates the expression of IL-23 in
the AM but not in PBMC derived macrophages, pointing to-
wards the importance of the cytokine in pulmonary infection
with the bacterium. Besides being able to permit the attachment,
entry and replication of HIV and MTB, AM also express a range
of immune factors, namely Th1 cytokines (IL-2 and IFN-g)or
Th2 cytokines (IL-4 and IL-10) in response to infection with
either or both pathogens [41]. These features make AM a
convenient model for HIV–MTB co-infections and related
drug discovery studies.
3.1.4. Human ex vivo T lymphocytes
While HIV-1 infects various cell types of the immune sys-
tem, CD4+ T helper cells constitute a major target for the virus.
CD4+ T cells express high levels of the HIV-1 receptor CD4 on
their surface and are highly permissive to HIV-1 replication [42].
Ex vivo human T lymphocytes and other immune cells obtained
from HIV–MTB infected and disease free individuals have been
used in studies on interactions between the two pathogens and
the human host [43]. Protocols to isolate and culture CD4+ and
CD8+ T cells from PBMCs are widely described. Primary
cultures of T lymphocytes obtained ex vivo have provided
vital clues on the pathogenesis of HIV and MTB.
Despite the limitations that are associated with these models,
the data gathered from primary cells in vitro can be readily
extrapolated to the in vivo disease situation. The fact that human
macrophages are a common reservoir for HIV andMTB validates
the use of these cells as models for HIV–MTB co-infections.
4. The potential of human-derived cell lines as models
for HIV–MTB co-infection studies
Studies have described the use of human derived cell models
in HIV and/or MTB research, including the use of (i) U937, [6]
(ii) T lymphocytes (CEMx174, ESAT-6-speciﬁc CD4+ T-cells),
[44,45] and (iii) alveolar epithelial cells (A549) [46,47]. U937
(American Type Culture Collection – ATCC® CRL1593.2™)
is a human monocyte-derived macrophage cell line that was
established from the pleural effusion of a patient with histiocytic
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CD15 and CD33, and mRNA for the c-myc oncogene [6]. The
use of U937 cells has led to the discovery of a number of
MTB proteins, including Rv2004c-6, Rv1510, [49] Rv1268c,
[46] and protein 16084, a peptide of Rv2707 [50]. Wang et al.
[51] used the U937 cell line to demonstrate that phosphotyrosyl
phosphatase activator (PtpA), phosphatase, is essential for the
pathogenesis of MTB. In the same studies, Wang et al. [52]
showed that MTB subverts the host innate immunity by co-
opting host ubiquitin, a pathway which can be exploited as a
drug target. The U937 cell line is therefore a convenient model
for HIV–MTB drug discovery and pathogenesis studies.
Interactions between HIV and MTB with their host have also
been demonstrated using the A549 cell line [44,52]. The use of
A549 in HIV-1 drug discovery studies has also been described
[51]. Using this cell line, protein arginine methyltransferase 6
(PRMT6) was shown to methylate the HIV-1 Tat and, hence,
to act as a restriction factor for HIV replication [47]. This has
shown the importance of the A549 cell line as a convenient
model for further studies on MTB/HIV pathogenesis,
including vaccine design.
4.1. Stem cells
To circumvent the limitations that are inherent in immortal-
ised and primary cell cultures as highlighted above, researchers
are now opting for stem cell technology as a viable alternative
for MTB/HIV pathogenesis/interaction studies. Stem cells are
pluripotent and non-specialised cells with the potential to
differentiate into other types of speciﬁc cells, such as blood,
brain, tissue or muscle cells [30]. Newer developments in the
ﬁeld have seen the development of induced pluripotent stem
cells (iPSC), which are genetically modiﬁed stem cells that
behave like embryonic stem cells [53]. Multiple studies have
reported a great potential of iPSC on interactions between
HIV–MTB with the host cells [54,55] and their use as
functional cure for HIV [56–58]. Recent developments have
shown that the incorporation of anti-HIV lentiviral vectors in
stem cells offers renewed hope for developing safer therapeutic
interventions with long-lived efﬁcacy against HIV [56,57]. Stem
cells are also a convenient tool for vaccine design against HIV
[58]. Stem cell based vaccine design protocols involve the
induction of somatic cells to iPSC, expansion of iPSC, genetic
or chemical modiﬁcation to produce immune cells, in vitro
antigen presentation and processing which culminate in the
production of memory B cells that can secrete functional
antibodies [58]. The generated cells are then transplanted back
into the host as a vaccine [58].
However, despite the recent expansion in the use of stem
cells in host–pathogen interactions, their use has not been
without limitations. The existing iPSC protocols do not allow for
efﬁcient direction of these cells into desired lineages [54].
Additionally, as in the case of primary cell culture models,
stem cell yields are frequently inadequate for each study [54].
The use of iPSC, like all other modiﬁed cell culture models,
has an inherent limitation in that outcomes from the model do
not fully mimic those of the disease [54] To circumvent these
obstacles, even newer approaches have been developed
including the use of three-dimensional (3D) organoid cultures
using iPSC, xenotransplantation of human cells into animal
models and multiple cell co-culture models that include cells
derived from isogenic iPSC.Nonetheless, the advantages of using stem cells out-weigh
the limitations highlighted above. As such, stem cells present
a great potential as models for vaccine design, particularly
against HIV-1.
4.2. Three dimensional (3D)/organoid models
Recent developments have made it possible to direct the
differentiation of human pluripotent stem cells (hPSC) into 3D
organoid cultures in vitro using a temporal series of growth
factor manipulations to mimic embryonic tissue development.
Lancaster et al. [59] reported the development of an hPSC
derived 3D brain organoid culture system (cerebral organoid),
which they claimed differentiates into various discrete, though
interdependent, brain regions. If validated, such a development
can serve as an essential tool to create various tissues that
mimic targets for HIV and MTB. Three dimensional (3D)
assays allow for the evaluation of host–pathogen interactions
in multicellular tissues.
In people infected with MTB, the bacterial cells are ‘walled
off’ in granulomas/tubercles away from the immune system [60].
There is a need to recreate conditions in vitro in order to
understand the reasons that underlie the long hibernation of
MTB in granulomas and the transition of MTB from latency
into active TB disease, and discover drugs that target the
bacterium in tubercles. The development of granulomas
in vitro using conventional cell cultures has been described
with variable success [61]. Guirado et al. [61] demonstrated the
development of granulomas from a human PBMC culture. Al
Shammari et al. [62] also described the development and use
of a 3D cell culture model of tuberculosis granuloma
formation. So far, the use of 3D iPSC technology in
granuloma formation has not been described. We perceive the
use of iPSC in 3D cell culture technology, with potential to
form granulomas, as a future for HIV–MTB research.
4.3. Human blood–brain barrier (BBB) cell model
HIV-1 is known to cross the BBB to invade the central
nervous system during the early stages of the viral infection,
which culminates in the impairment of neurons, becoming
evident several years later [63]. A number of models that simulate
the BBB for HIV research have been described [63]. Persidsky
et al. [63] describes a model of the BBB consisting of a
matrix-coated membrane with brain microvascular endothelial
(BMVEC) cells on one side and astrocytes on the other. This
model demonstrated the formation of tight junctions between the
astrocytes and the monolayer of BMVEC cells, the development
of ﬁlopodia, lysosomes, and vesicular Golgi complexes, and the
upregulation of proinﬂammatory cytokines (TNF-a, IL-6, and
IL-10) [64]. Cell culture models can therefore be useful tools for
studying the entry of HIV across the BBB.
5. The potential of primary murine cell cultures as
models for HIV–MTB co-infection studies
5.1. Mouse primary cells and cell lines
The use of mice in HIV research is limited by the lack of
infectivity of the mice cells by HIV, lack of factors necessary for
HIV-1 replication and the expression factors that interfere with
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cell lines in HIV research has been described, including the
macrophage cell lines RAW 264.7 (ATCC® TIB71™), [64]
J774.2 (ATCC® TIB-67™), [65] ﬁbroblast cell lines including
NIH 3T3 (ATCC® CRL1658™), [66] C3H clones (ATCC®
CCL226™ and ATCC® CRL1411™), embryonic ﬁbroblast cell
lines, [67] T-lymphoma cell lines S1A.TB, TIMI.4 and R1.1.
Despite the fact that mouse T cells restrict the integration of
virus genome during replication, RAW 264.7 cells has
frequently been described in HIV research, especially in
pathogenesis and drug discovery studies [64]. The use of RAW
264.7 cells in MTB research is also described [68]. Another
murine macrophage cell line, J774.2 (ATCC® TIB-67™), has
also found a place in HIV and TB research. The use of J774.2
cells has been described in multiple studies, including drug
discovery against HIV and MTB [69,70].
5.2. Rattus cell line models for MTB and HIV studies
Only a few rat cell lines have been used in HIV and TB
research, especially XC (ATCC® CCL-165™) [71,72]. A study
by Gofﬁnet et al. [71] showed that rat cells (Rat2, RGE, XC
and HH16) complete all of the early steps in the HIV-1 repli-
cation cycle, including provirus integration in vivo, with high
efﬁciency and elevated HIV gene expression in primary rat T-
cells. However, a study by Bieniasz and Cullen [73] showed that
HIV-1 has limited entry efﬁciency in rat cells. Hino et al. [72]
demonstrated that BCG-infected rat alveolar cells (NR8383)
are a potential in vitro model for chronic infection with MTB.
The fact that rat cell lines have limited permissibility for HIV
entry makes them a less preferred model for HIV–MTB research
compared to human cell models.
5.3. Cavine cell lines for MTB and HIV studies
Guinea pigs, besides being used as animal models for various
diseases including TB and HIV, are also widely used as a source
of cell cultures for studies on the pathogenesis of MTB [74]. A
protocol to isolate AM from guinea pigs, which includes a
bronchoalveolar lavage technique, is widely described [74].
The guinea pig AM cells may be a more ethically acceptable
model for host pathogen interactions than human derived cell
lines and primary cultures.
6. The potential of cell culture models in high
throughput studies of HIV–MTB co-infections
High throughput techniques, which incorporate automation
of experiments to allow large scale repetitions in tests including
cell-based arrays, have become a new frontier for drug discovery
[75]. Christophe et al. [76] described a high-throughput and high-
content workﬂow, which incorporates the use of cell culture and
imaging technology in the development of new TB drugs. Jiang
et al. [77] also described a high throughput method that uses
human embryonic kidney 293 (HEK293T) cells to study gene
expression in the presence of HIV. High throughput
techniques can be adapted to any cell model that is permissive
to attachment, entry or replication of HIV and MTB. The high
throughput technique is an essential addition to cell culture
modelling, which permits researchers to obtain reliable results
faster.7. Conclusion
Cell culture models, especially those of human origin, have
great potential as models to study interactions between HIV
and MTB in co-infected individuals, or to study host re-
sponses to either or both pathogens. Human macrophages,
including AM and MDM, bear an unparalleled potential as
models for these co-infections due to their permissiveness for
HIV and MTB attachment, entry and replication, and their
capacity to elicit host speciﬁc cell-based immunity in the
presence of either or both pathogens. Rat and mouse cell
cultures offer limited potential since they do not efﬁciently
support all stages of HIV replication. The exploitation of stem
cell technologies such as iPSC, whose differentiation can be
directed as desired and 3D cell culture models are recent
developments that have provided a new dimension to the ﬁeld
of host–pathogen interactions. The incorporation of high
throughput technologies to cell culture modelling has pushed
the frontiers of HIV–MTB co-infection research allowing re-
searchers to have more options for host–pathogen interaction
studies. While multiple cell culture models are available for
host-HIV–MTB interaction studies, the complexity of such
interactions demands the development and validation of more
cell culture models.
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